Press release: SGS launches SGS PACE, a streamlined pathway through preclinical, formulation, FIH and POC
SGS PACE is a seamless combination of world-leading development, bioanalysis and clinical research through one point of contact.
List view / Grid view
SGS PACE is a seamless combination of world-leading development, bioanalysis and clinical research through one point of contact.
20 April 2023 | By Charles River Laboratories
Doug Botkin, PhD, examines the challenges and consequences of inaccurate microbial identification methods using real-world case studies and discusses how these challenges can be addressed.
A new collaboration between two industry players for cGMP production of 3D screen printing technologies could reduce drug development costs.
Virtual seminar presented by Ziva Abraham, President, and CEO of Microrite designed to improve your understanding on current regulatory thinking on designing an effective contamination control strategy.
Two Big Pharma companies and one CDMO have been awarded the Terra Carta Seal, which recognises the efforts of global companies in their commitment to sustainability.
Imaweld® is distinct due to its composition, which seals and welds tubes and highly endorsed in biopharma for cell membrane and cell culture applications
Charles River launches Endosafe Nexus 200, emphasises the importance of automated endotoxin testing systems to improve the efficiency of QC labs.
See how consolidating your forced degradation data into a single interface can improve your pharmaceutical stress testing research.
ImaLINK™ manifold, which is designed to minimise the need for fittings, connections or assembly of all leak points, entrapment areas are eliminated.
Private equity overhang to fuel CDMO valuations and expansions, while venture capital overhang will fuel continued demand for services in spite of adverse global conditions.
First-in-human clinical verification is one of the first critical milestones in drug development. Abhijeet Sinha, Senior Scientist at Lonza Small Molecules, exemplifies the imperative of solving drug development challenges in the early phases.
Report out ahead of CPHI Frankfurt predicts ‘biologics outsourcing to surge in 2023, as China’s innovation engine stalls.'
In this Guide to Outsourcing & Testing, EPR explores trends in the pharmaceutical outsourcing market. Plus, Charles River discusses solutions for tracking, trending and microbial identification and Associates of Cape Cod International showcases its endotoxin testing capabilities.
Near-term gains from outsourcing biopharma R&D activities can be offset by slower innovation in the long run, according to a recent paper.
Rising demand for cancer drugs, combined with high in-house manufacturing costs is driving growth in the high-potency API outsourcing market.